128372-89-4

Basic information

• Product Name: tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate;tert-Butyl 2-oxo-5,6-dihydropyridine-1(2H)
• CAS NO: 128372-89-4
• Molecular Formula: C₁₀H₁₅NO₃
• Molecular Weight: 197.231
• Mol File: 128372-89-4.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 262.3±33.0 °C(Predicted)
• Appearance: /
• Density: 1.130±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.75±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate(128372-89-4)
• EPA Substance Registry System: tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate(128372-89-4)

Safety Data

• Hazardous Substances Data: 128372-89-4(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate is a chemical compound with the molecular formula C12H17NO3. It is a dihydropyridine derivative that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate is known for its potential as a calcium channel blocker, which makes it useful in the treatment of cardiovascular diseases such as hypertension and angina. Tert-butyl 2-oxo-5,6-dihydropyridine-1(2H)-carboxylate is also used as a building block in the preparation of various organic compounds, making it a versatile and valuable chemical in the field of medicinal and synthetic chemistry.

Upstream product

• 1372716-04-5 tert-butyl 6-[(diphenoxyphosphoryl)oxy]-3,4-dihydropyridine-1(2H)-carboxylate 
• 131667-57-7 tert-butyl 1,2,3,4-tetrahydro-1-pyridinecarboxylate 
• 1245646-10-9 tert-butyl 4-hydroxy-2-oxopiperidine-1-carboxylate 
• 845267-78-9 tert-butyl 2,4-dioxopiperidine-1-carboxylate 
• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 1415686-28-0 N-(but-3-en-1-yl)prop-2-enamide 
• 1215765-59-5 tert-butyl 2-oxo-3-(phenylselanyl)piperidine-1-carboxylate 
• 831227-07-7 6-trimethylsilanyloxy-3,4-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 358732-56-6 N-(tert-butyloxycarbonyl)-3-(phenylthio)piperidine-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 675-20-7 piperidin-2-one 
• 85908-96-9 2-oxopiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 6052-73-9 5,6-dihydro-2(1H)-pyridinone 
• 1226623-45-5 tert-butyl 6-oxo-5-[(2E)-3-phenyl-2-propen-1-yl]-3,6-dihydropyridine-1(2H)-carboxylate 
• 1229643-25-7 2,2'-dioxo-5,6,3',4',5',6'-hexahydro-2H,2'H-[3,4]bipyridinyl-1,1'-dicarboxylic acid di-tert-butyl ester 

Relevant articles and documents

A facile approach to α,β-unsaturated lactams by ring-closing metathesis

[MediaObject not available: see fulltext.]A facile and efficient strategy for the synthesis of α,β-unsaturated lactams through ring-closing metathesis of easily prepared diene amides is being reported here. Reaction conditions were optimized for metathetic cyclization of diene amides to obtain five- to sevenmembered unsubstituted and β-substituted α,β-unsaturated lactams in good to excellent yield.

Synthesis of a novel tripeptidomimetic scaffold and biological evaluation for CXC chemokine receptor 4 (CXCR4) antagonism

We here report the preparation of a new 2,6,8-trisubstituted bicyclic tripeptidomimetic scaffold through TFA-mediated cyclization of a linear precursor containing three side chains. The introduction of a triphenylmethyl-protected thiol into carboxylic aci

Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor

Targeting the Trp-Kyn pathway is an attractive approach for cancer immunotherapy. Thioredoxin reductase (TrxR) enzymes are reactive oxygen species (ROS) modulators that are involved in the tumor cell growth and survival processes. The 4-phenylimidazole scaffold is well-established as useful for indoleamine 2,3-dioxygenase 1 (IDO1) inhibition, while piperlongumine (PL) and its derivatives have been reported to be inhibitors of TrxR. To take advantage of both immunotherapy and TrxR inhibition, we designed a first-generation dual IDO1 and TrxR inhibitor (ZC0101) using the structural combination of 4-phenylimidazole and PL scaffolds. ZC0101 exhibited better dual inhibition against IDO1 and TrxR in vitro and in cell enzyme assays than the uncombined forms of 4-phenylimidazole and PL. It also showed antiproliferative activity in various cancer cell lines, and a selective killing effect between normal and cancer cells. Furthermore, ZC0101 effectively induced apoptosis and ROS accumulation in cancer cells. Knockdown of TrxR1 and IDO1 expression induced cellular enzyme inhibition and ROS accumulation effects during ZC0101 treatment, but only reduced TrxR1 expression was able to improve ZC0101′s antiproliferation effect. This proof-of-concept study provides a novel strategy for cancer treatment. ZC0101 represents a promising lead compound for the development of novel antitumor agents that can also be used as a valuable probe to clarify the relationships and mechanisms of cancer immunotherapy and ROS modulators.

CCR2 MODULATORS

Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I) and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of CCR2 receptors.